Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) at JCI accreditated and Top-10 Hospitals 2025 by Newsweek Hospital

• Terapia con cellule CAR-T
• 3 pasti al giorno dal nutrizionista
• Servizi infermieristici 24 ore su 24
• Elettrocardiogramma (ECG)
• Esami del sangue
• Radiografia del torace
• Test anti-HIV
• Test Anti-HBC
• Test Anti-HCVAb
• Ecocardiografia
• Esame di biochimica del sangue
• Consultazione con un oncologo
• Consultazione con un ematologo
• Consultazione con un immunologo
• Consultazione con un cardiologo
• Consultazione con un ematologo pediatrico
• Consultazione con un pediatra
• Consultazione con un oncoematologo
• Risonanza magnetica della testa
• Biopsia

• 21 giorni in ospedale

• Trasferimento aeroporto-clinica-aeroporto

Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL)

At Sheba Medical Center, children and young patients with Non-Hodgkin lymphomas have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program focuses on treating diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), especially in relapsed or treatment-resistant cases using highly personalized immunotherapy.

A Personalized Treatment Designed for Each Child

CAR-T therapy uses the patient’s own immune system to identify and destroy cancer cells. This approach offers new hope for children and young patients when standard therapies are no longer effective.

At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality:

Apheresis – collection of the patient’s T-cells
Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target lymphoma

Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body over time and offering the potential for long-term remission.

Expert Pediatric Leadership and Care

The pediatric CAR-T program is led by Prof. Amos Toren, one of the most experienced specialists in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed.

The program includes:

Dedicated pediatric CAR-T units with 24/7 expert monitoring
A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists
A supportive, family-centered environment designed for children
Full international patient support, including travel and care coordination
Proven Outcomes and Global Expertise

Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes:

~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults

The program is highly experienced in treating complex and high-risk lymphoma cases, offering advanced options when other treatments have been exhausted.

Comprehensive Evaluation and Support

Each child undergoes a thorough diagnostic evaluation, including:
advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment.

Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed at every stage.

A Trusted Place for Advanced Pediatric Cancer Care

By combining cutting-edge science, rapid access to treatment, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Non-Hodgkin lymphomas with CAR-T therapy focused on achieving remission and helping children return to a healthy, active life.

• Coordinatore medico personale
• Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
• Tutela degli interessi dei pazienti durante il viaggio medico